MX2015014538A - Moleculas de union a antigenos trimericas. - Google Patents

Moleculas de union a antigenos trimericas.

Info

Publication number
MX2015014538A
MX2015014538A MX2015014538A MX2015014538A MX2015014538A MX 2015014538 A MX2015014538 A MX 2015014538A MX 2015014538 A MX2015014538 A MX 2015014538A MX 2015014538 A MX2015014538 A MX 2015014538A MX 2015014538 A MX2015014538 A MX 2015014538A
Authority
MX
Mexico
Prior art keywords
antigen binding
binding molecules
trimeric antigen
trimeric
methods
Prior art date
Application number
MX2015014538A
Other languages
English (en)
Inventor
Ekkehard Moessner
Pablo Umana
Peter Bruenker
Claudia Ferrara Koller
Sandra Grau-Richards
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2015014538A publication Critical patent/MX2015014538A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención pertenece a una molécula de unión a antígenos trimérica que comprende tres polipéptidos de fusión, cada uno que comprende por lo menos una porción de unión a antígenos fusionada a un dominio de trimerización derivado de una proteína de la matriz del cartílago humana. Además, la presente invención se refiere a polipéptidos que codifican estas moléculas de unión a antígenos triméricas y vectores y células hospedantes que comprenden estos polinucleótidos. La invención se refiere además a métodos para producir las moléculas de unión a antígenos triméricas de la invención y a métodos para utilizar estas moléculas de unión a antígenos triméricas en el tratamiento de una enfermedad.
MX2015014538A 2013-05-07 2014-05-05 Moleculas de union a antigenos trimericas. MX2015014538A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13166793 2013-05-07
PCT/EP2014/059030 WO2014180754A1 (en) 2013-05-07 2014-05-05 Trimeric antigen binding molecules

Publications (1)

Publication Number Publication Date
MX2015014538A true MX2015014538A (es) 2016-02-05

Family

ID=48227070

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014538A MX2015014538A (es) 2013-05-07 2014-05-05 Moleculas de union a antigenos trimericas.

Country Status (10)

Country Link
US (1) US9975958B2 (es)
EP (1) EP2994487B1 (es)
JP (1) JP6618463B2 (es)
KR (1) KR20160005345A (es)
CN (1) CN105377893A (es)
CA (1) CA2907597A1 (es)
HK (1) HK1222182A1 (es)
MX (1) MX2015014538A (es)
RU (1) RU2015152077A (es)
WO (1) WO2014180754A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG187746A1 (en) 2010-08-13 2013-03-28 Roche Glycart Ag Anti-fap antibodies and methods of use
PE20140303A1 (es) 2011-02-10 2014-03-22 Roche Glycart Ag Polipeptidos interleuquina-2 mutantes
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
MX2017004526A (es) * 2014-10-08 2017-06-07 Hoffmann La Roche Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos.
EP3224275B1 (en) 2014-11-14 2020-03-04 F.Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer
US10689449B2 (en) * 2015-01-20 2020-06-23 Igm Biosciences, Inc. Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
AU2015380455A1 (en) * 2015-01-26 2017-08-03 Macrogenics, Inc. Multivalent molecules comprising DR5-binding domains
WO2016156291A1 (en) 2015-03-31 2016-10-06 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a trimeric tnf family ligand
CN115057936A (zh) * 2015-06-15 2022-09-16 努玛治疗有限公司 异源二聚体多特异性抗体形式
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
BR112018002570A2 (pt) 2015-10-02 2018-10-16 Hoffmann La Roche molécula de ligação ao antígeno biespecífica, anticorpo biespecífico, polinucleotídeos, anticorpo que se liga especificamente ao ox40, composição farmacêutica e método para inibir o crescimento de células tumorais em um indivíduo
WO2017104796A1 (ja) * 2015-12-16 2017-06-22 国立大学法人 岡山大学 人工ｒｎａ制限酵素
EP3243836A1 (en) * 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
JP2019205355A (ja) * 2016-09-30 2019-12-05 国立大学法人名古屋大学 分子改変体アディポネクチン及び分子改変体アディポネクチンを含む医薬組成物
WO2018178074A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules specific for a costimulatory tnf receptor
BR112019017753A2 (pt) * 2017-04-04 2020-04-07 Hoffmann La Roche molécula biespecífica, polinucleotídeo, vetor, célula, métodos para a produção de uma molécula e para o tratamento de um indivíduo, composição e uso da molécula biespecífica
WO2018212556A1 (en) * 2017-05-16 2018-11-22 Cj Healthcare Corporation A method for purifying an antibody or an antibody fragment thereof using affinity chromatography
US11590219B2 (en) 2018-01-30 2023-02-28 Emory University Compositions and methods for promoting immune responses to human immunodeficiency virus
CN114409803B (zh) * 2020-12-31 2023-10-20 中国科学院微生物研究所 流感病毒三聚体亚单位疫苗及其应用
CN114409802B (zh) * 2020-12-31 2023-10-20 中国科学院微生物研究所 禽流感病毒三聚体亚单位疫苗及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10045591A1 (de) 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
AU2011265482B2 (en) * 2005-05-06 2013-08-29 Providence Health & Services - Oregon Trimeric OX40L-immunoglobulin fusion protein and methods of use
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
US10183986B2 (en) * 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
CN101830986A (zh) * 2009-03-13 2010-09-15 北京表源生物技术有限公司 一种融合蛋白多聚体
CN102250254A (zh) * 2010-05-19 2011-11-23 江苏先声药物研究有限公司 肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用
EP3670536A3 (en) * 2011-04-01 2020-10-07 Universität Stuttgart Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof
WO2012140627A1 (en) * 2011-04-15 2012-10-18 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer

Also Published As

Publication number Publication date
US9975958B2 (en) 2018-05-22
EP2994487A1 (en) 2016-03-16
CN105377893A (zh) 2016-03-02
JP6618463B2 (ja) 2019-12-11
EP2994487B1 (en) 2019-10-09
RU2015152077A (ru) 2017-06-13
WO2014180754A1 (en) 2014-11-13
JP2016520055A (ja) 2016-07-11
KR20160005345A (ko) 2016-01-14
US20160159917A1 (en) 2016-06-09
CA2907597A1 (en) 2014-11-13
HK1222182A1 (zh) 2017-06-23

Similar Documents

Publication Publication Date Title
MX2015014538A (es) Moleculas de union a antigenos trimericas.
PH12014502767A1 (en) Interleukin-2 fusion proteins and uses thereof
PH12017500939A1 (en) T cell activating bispecific antigen binding molecules agiant folr1 and cd1
PH12015500284A1 (en) Interleukin-10 fusion proteins and uses thereof
PH12018500634A1 (en) Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
PH12016502505A1 (en) Bispecific t cell activating antigen binding molecules
PH12015501340A1 (en) Bispecific t cell activating antigen binding molecules
BR112014019579A8 (pt) Anticorpos, polinucleotídeos, vetores, métodos de produção de um anticorpo, heteromultímero, método de produção de um heteromultímero e célula hospedeira
MX2015010843A (es) Moleculas biespecificas de union al antigeno que activan celulas t.
MX2015010350A (es) Moleculas de union a antigeno biespecificas que activan la celula t.
EA201491494A1 (ru) Нацеливание на гликаны хондроитинсульфаты
MY171038A (en) Bispecific antigen binding molecules
MX357327B (es) Proteinas de union a antigenos del ligando de cd30 humano.
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
MX352101B (es) Moleculas biespecificas de union a antigeno activadoras de celulas t.
IL294314A (en) Proteins based on the scaffolding domain of fibronectin that bind to myostatin
EA201400964A1 (ru) Cx3cr1-связывающие полипептиды
EA201590136A1 (ru) Искусственные консенсусные альбумин-связывающие домены
EA202091198A1 (ru) Полипептиды, содержащие домен d, и их применение
MY166157A (en) Antibodies to bradykinin b1 receptor ligands
MX366178B (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
CL2009000862A1 (es) Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer.
MX2016002166A (es) Anticuerpos.
PH12019502274A1 (en) Antibodies binding to steap-1